1	COMMITTEE SUBSTITUTE
2	FOR
3	COMMITTEE SUBSTITUTE
4	FOR
5	Senate Bill No. 6
6	(By Senators Tucker, Kessler (Mr. President), Stollings, Laird
7	and Plymale)
8	
9	[Originating in the Committee on the Judiciary;
10	reported February 13, 2014.]
11	
12	
13	
14	A BILL to repeal §60A-10-8 of the Code of West Virginia, 1931, as
15	amended; to amend and reenact §60A-2-210 and §60A-2-212 of
16	said code; and to amend and reenact §60A-10-2, §60A-10-3,
17	\$60A-10-4, $$60A-10-5$ and $$60A-10-7$ of said code, all relating
18	to the Methamphetamine Lab Eradication Act and the prevention
19	of the production of methamphetamine generally; requiring
20	certain drug products containing ephedrine, pseudoephedrine or
21	phenylpropanolamine be obtained by prescription only; moving
22	said drug products from Schedule V to Schedule IV;
23	distinguishing between schedule classifications; providing an
24	exception for drug products that are extraction or conversion

resistant; making legislative findings; defining terms; prohibiting pharmacies from selling certain drugs that can be production of methamphetamine the creating criminal offenses prescription; related to methamphetamine and establishing precursors penalties therefor; permitting the sale of certain drugs without a prescription where the Board of Pharmacy determines that the drugs are not feasible for being used for the manufacture of methamphetamine; reducing the maximum amounts persons are permitted to purchase of certain drugs that cannot feasibly be converted into methamphetamine; limiting authority of the Board of Pharmacy as to storage, recordkeeping and security requirements for wholesalers; adjusting the requirements of the Multi-State Real-Time Tracking System; removing certain outdated language; and providing rule-making authority to the Board of Pharmacy to implement emergency and legislative rules, which will provide procedures as to which products may be sold over the counter and which require a prescription and other modifications necessary to implement the Methamphetamine Lab Eradication Act.

21 Be it enacted by the Legislature of West Virginia:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

22 That \$60A-10-8 of the Code of West Virginia, 1931, as amended, 23 be repealed; that \$60A-2-210 and \$60A-2-212 of said code be amended 24 and reenacted; and that \$60A-10-2, \$60A-10-3, \$60A-10-4, \$60A-10-5

- 1 and §60A-10-7 of said code be amended and reenacted, all to read as 2 follows:
- 3 ARTICLE 2. STANDARDS AND SCHEDULES.
- 4 §60A-2-210. Schedule IV.
- 5 (a) Schedule IV shall consist of the drugs and other 6 substances, by whatever official name, common or usual name, 7 chemical name or brand name designated, listed in this section.
- 8 (b) Narcotic drugs. -- Unless specifically excepted or unless
 9 listed in another schedule, any material, compound, mixture or
 10 preparation containing any of the following narcotic drugs, or
 11 their salts calculated as the free anhydrous base or alkaloid, in
 12 limited quantities as set forth below:
- 13 (1) Not more than 1 milligram of different and not less than
 14 25 micrograms of atropine sulfate per dosage unit;
- 15 (2) Dextropropoxyphene
 16 (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybuta
 17 ne).
- 18 (c) Depressants. -- Unless specifically excepted or unless
 19 listed in another schedule, any material, compound, mixture or
 20 preparation which contains any quantity of the following
 21 substances, including its salts, isomers and salts of isomers
 22 whenever the existence of such salts, isomers and salts of isomers
 23 is possible within the specific chemical designation:
- 24 (1) Alprazolam;

- 1 (2) Barbital;
- 2 (3) Bromazepam;
- 3 (4) Camazepam;
- 4 (5) Carisoprodol;
- 5 (6) Chloral betaine;
- 6 (7) Chloral hydrate;
- 7 (8) Chlordiazepoxide;
- 8 (9) Clobazam;
- 9 (10) Clonazepam;
- 10 (11) Clorazepate;
- 11 (12) Clotiazepam;
- 12 (13) Cloxazolam;
- 13 (14) Delorazepam;
- 14 (15) Diazepam;
- 15 (16) Estazolam;
- 16 (17) Ethchlorvynol;
- 17 (18) Ethinamate;
- 18 (19) Ethyl loflazepate;
- 19 (20) Fludiazepam;
- 20 (21) Flunitrazepam;
- 21 (22) Flurazepam;
- 22 (23) Halazepam;
- 23 (24) Haloxazolam;
- 24 (25) Ketazolam;

```
1 (26) Loprazolam;
```

- 2 (27) Lorazepam;
- 3 (28) Lormetazepam;
- 4 (29) Mebutamate;
- 5 (30) Medazepam;
- 6 (31) Meprobamate;
- 7 (32) Methohexital;
- 8 (33) Methylphenobarbital (mephobarbital);
- 9 (34) Midazolam;
- 10 (35) Nimetazepam;
- 11 (36) Nitrazepam;
- 12 (37) Nordiazepam;
- 13 (38) Oxazepam;
- 14 (39) Oxazolam;
- 15 (40) Paraldehyde;
- 16 (41) Petrichloral;
- 17 (42) Phenobarbital;
- 18 (43) Pinazepam;
- 19 (44) Prazepam;
- 20 (45) Quazepam;
- 21 (46) Temazepam;
- 22 (47) Tetrazepam;
- 23 (48) Triazolam;
- 24 (49) Zolpidem.

- 1 (d) Fenfluramine. -- Any material, compound, mixture or 2 preparation which contains any quantity of the following substance, 3 including its salts, isomers (whether optical, position or 4 geometric) and salts of such isomers whenever the existence of such 5 salts, isomers and salts of isomers is possible: Fenfluramine.
- 6 (e) Stimulants. -- Unless specifically excepted or unless 7 listed in another schedule, any material, compound, mixture or 8 preparation which contains any quantity of the following substances 9 having a stimulant effect on the central nervous system, including 10 its salts, isomers and salts of isomers:
- 11 (1) Cathine ((+)-norpseudoephedrine);
- 12 (2) Diethylpropion;
- 13 (3) Fencamfamin;
- 14 (4) Fenproporex;
- 15 (5) Mazindol;
- 16 (6) Mefenorex;
- 17 (7) Pemoline (including organometallic complexes and chelates 18 thereof);
- 19 (8) Phentermine;
- 20 (9) Pipradrol;
- 21 (10) SPA ((-)-1-dimethylamino-1, 2-diphenylethane).
- (f) Any compound, mixture or preparation containing ephedrine, 23 pseudoephedrine or phenylpropanolamine, their salts or optical 24 isomers, or salts of optical isomers except products which are for

- 1 pediatric use primarily intended for administration to children
 2 under the age of twelve: Provided, That neither the offenses set
 3 forth in section four hundred one, article four of this chapter, nor
 4 the penalties therein, shall be applicable to ephedrine,
 5 pseudoephedrine or phenylpropanolamine, that shall be subject to the
 6 provisions of article ten of this chapter.
- 7 (f) (g) Other substances. -- Unless specifically excepted or 8 unless listed in another schedule, any material, compound, mixture 9 or preparation which contains any quantity of the following 10 substances, including its salts:
- 11 (1) Pentazocine;
- 12 (2) Butorphanol.
- Amyl nitrite, butyl nitrite, isobutyl nitrite and the other 14 organic nitrites are controlled substances and no product containing 15 these compounds as a significant component shall be possessed, 16 bought or sold other than pursuant to a bona fide prescription or 17 for industrial or manufacturing purposes.

18 **§60A-2-212**. **Schedule V**.

- 19 (a) Schedule V shall consist of the drugs and other substances, 20 by whatever official name, common or usual name, chemical name or 21 brand name designated, listed in this section.
- 22 (b) Narcotic drugs. -- Unless specifically excepted or unless 23 listed in another schedule, any material, compound, mixture or 24 preparation containing any of the following narcotic drugs and their

1 salts, as set forth below:

- 2 (1) Buprenorphine.
- 3 (c) Narcotic drugs containing nonnarcotic active medicinal 4 ingredients. -- Any compound, mixture or preparation containing any 5 of the following narcotic drugs or their salts calculated as the 6 free anhydrous base or alkaloid in limited quantities as set forth 7 below, which shall include one or more nonnarcotic active medicinal 8 ingredients in sufficient proportion to confer upon the compound, 9 mixture or preparation valuable medicinal qualities other than those 10 possessed by the narcotic drug alone:
- 11 (1) Not more than 200 milligrams of codeine per 100 milliliters 12 or per 100 grams;
- 13 (2) Not more than 100 milligrams of dihydrocodeine per 100 14 milliliters or per 100 grams;
- 15 (3) Not more than 100 milligrams of ethylmorphine per 100 16 milliliters or per 100 grams;
- 17 (4) Not more than 2.5 milligrams of diphenoxylate and not less 18 than 25 micrograms of atropine sulfate per dosage unit;
- 19 (5) Not more than 100 milligrams of opium per 100 milliliters 20 or per 100 grams;
- 21 (6) Not more than 0.5 milligrams of different and not less than 2225 micrograms of atropine sulfate per dosage unit.
- 23 (d) Stimulants. -- Unless specifically exempted or excluded or 24 unless listed in another schedule, any material, compound, mixture

1 or preparation which contains any quantity of the following 2 <u>substances</u> <u>substance</u> having a stimulant effect on the central 3 nervous system, including its salts, isomers and salts of isomers: 4 (1) Pyrovalerone.

(e) Any compound, mixture or preparation containing as its single active ingredient ephedrine, pseudoephedrine or 7 phenylpropanolamine, their salts or optical isomers, or salts of 8 optical isomers except products which are for pediatric use 9 primarily intended for administration to children under the age of 10 twelve: Provided, That neither the offenses set forth in section 11 four hundred one, article four of this chapter, nor the penalties 12 therein, shall be applicable to ephedrine, pseudoephedrine or 13 phenylpropanolamine, which shall be subject to the provisions of 14 article ten of this chapter.

15 ARTICLE 10. METHAMPHETAMINE LABORATORY ERADICATION ACT.

16 §60A-10-2. Purpose; findings.

- 17 The Legislature finds:
- 18 (a) That the illegal production and distribution of 19 methamphetamine is an increasing problem nationwide and particularly 20 prevalent in rural states such as West Virginia.
- 21 (b) That methamphetamine is a highly addictive drug that can 22 be manufactured in small and portable laboratories. These 23 laboratories are operated by individuals who manufacture the drug 24 in a clandestine and unsafe manner, often resulting in explosions

1 and fires that can injure not only the individuals involved, but 2 their families, neighbors, law-enforcement officers and firemen.

- 3 (c) That use of methamphetamine can result in fatal kidney and 4 lung disorders, brain damage, liver damage, blood clots, chronic 5 depression, hallucinations, violent and aggressive behavior, 6 malnutrition, disturbed personality development, deficient immune 7 system and psychosis. Children born to mothers who are abusers of 8 methamphetamine can be born addicted and suffer birth defects, low 9 birth weight, tremors, excessive crying, attention deficit disorder 10 and behavior disorders.
- 11 (d) That in addition to the physical consequences to an 12 individual who uses methamphetamine, usage of the drug also produces 13 an increase in automobile accidents, explosions and fires, increased 14 criminal activity, increased medical costs due to emergency room 15 visits, increases in domestic violence, increased spread of 16 infectious diseases and a loss in worker productivity.
- 17 (e) That environmental damage is another consequence of the 18 methamphetamine epidemic. Each pound of methamphetamine produced 19 leaves behind five to six pounds of toxic waste. Chemicals and 20 byproducts that result from the manufacture of methamphetamine are 21 often poured into plumbing systems, storm drains or directly onto 22 the ground. Clean up of methamphetamine laboratories is extremely 23 resource intensive, with an average remediation cost of \$5,000.
- 24 (f) That it is in the best interest of every West Virginian to

1 develop a viable solution to address the growing methamphetamine 2 problem in the State of West Virginia. The Legislature finds that 3 extraction- or conversion-resistant pseudoephedrine hydrocloride can 4 provide a nonprescription option that is less readily usable in the 5 manufacture of methamphetamine. The Legislature finds that 6 restricting access to over-the-counter requiring a prescription for 7 drugs that can be readily converted used to facilitate production 8 of methamphetamine is necessary to protect the public safety of all 9 West Virginians.

10 (g) That it is further in the best interests of every West 11 Virginian to create impediments to the manufacture of 12 methamphetamine by requiring persons purchasing chemicals necessary 13 to the process to provide identification.

14 \$ 60A-10-3. Definitions.

- 15 In this article:
- 16 (a) "Board of Pharmacy" or "board" means the West Virginia 17 Board of Pharmacy established by the provisions of article five, 18 chapter thirty of this code.
- 19 (b) "Designated precursor" means any drug product made subject 20 to the requirements of this article by the provisions of section ten 21 seven of this article.
- (c) "Distributor" means any person within this state or another 23 state, other than a manufacturer or wholesaler, who sells, delivers, 24 transfers or in any manner furnishes a drug product to any person

1 who is not the ultimate user or consumer of the product.

- 2 (d) "Drug product" means a pharmaceutical product that contains 3 ephedrine, pseudoephedrine or phenylpropanolamine or a substance 4 identified on the supplemental list provided in section seven of 5 this article which may be sold without a prescription and which is 6 labeled for use by a consumer in accordance with the requirements 7 of the laws and rules of this state and the federal government.
- 8 (e) "Ephedrine" means ephedrine, its salts or optical isomers
 9 or salts of optical isomers.
- (f) "Extraction or conversion resistant" means a product 11 containing ephedrine, pseudoephedrine or phenylpropanolamine that 12 because of its compounding, preparation, mixture or ingredients has 13 been found by the Board of Pharmacy to pose a significantly reduced 14 risk of being used in the manufacture of methamphetamine.
- (f) (g) "Manufacturer" means any person within this state who 16 produces, compounds, packages or in any manner initially prepares 17 for sale or use any drug product or any such person in another state 18 if they cause the products to be compounded, packaged or transported 19 into this state.
- (g) (h) "National Association of Drug Diversion Investigators"
 21 or "NADDI" means the nonprofit 501(c)(3) organization established
 22 in 1989, made up of members who are responsible for investigating
 23 and prosecuting pharmaceutical drug diversion, and that facilitates
 24 cooperation between law enforcement, health care professionals,

1 state regulatory agencies and pharmaceutical manufacturers in the 2 investigation and prevention of prescription drug abuse and 3 diversion.

- 4 (h) (i) "Multi-State Real-Time Tracking System" or "MSRTTS"
 5 means the real-time electronic logging system provided by NADDI at
 6 no cost to states that have legislation requiring real-time
 7 electronic monitoring of precursor purchases, and agree to use the
 8 system. MSRTTS is used by pharmacies and law enforcement to track
 9 sales of over-the-counter (OTC) cold and allergy medications
 10 containing precursors to the illegal drug methamphetamine.
- 11 (i) (j) "Phenylpropanolamine" means phenylpropanolamine, its 12 salts, optical isomers and salts of optical isomers.
- 13 (j) (k) "Pseudoephedrine" means pseudoephedrine, its salts, 14 optical isomers and salts of optical isomers.
- (k) (l) "Precursor" means any substance which may be used along 16 with other substances as a component in the production and 17 distribution of illegal methamphetamine.
- (1) (m) "Pharmacist" means an individual currently licensed by 19 this state to engage in the practice of pharmacist care as defined 20 in article five, chapter thirty of this code.
- 21 (m) (n) "Pharmacy intern" has the same meaning as the term 22 "intern" as set forth in section one-b four, article five, chapter 23 thirty of this code.
- 24 (n) (o) "Pharmacy" means any drugstore, apothecary or place

1 within this state where drugs are dispensed and sold at retail or 2 display for sale at retail and pharmacist care is provided outside 3 of this state where drugs are dispensed and pharmacist care is 4 provided to residents of this state.

- 5 (o) (p) "Pharmacy counter" means an area in the pharmacy 6 restricted to the public where controlled substances are stored and 7 housed and where controlled substances may only be sold, transferred 8 or dispensed by a pharmacist, pharmacy intern or pharmacy 9 technician.
- 10 (p) (q) "Pharmacy technician" means a registered technician who 11 meets the requirements for registration as set forth in article 12 five, chapter thirty of this code.
- 13 (q) (r) "Retail establishment" means any entity or person 14 within this state who sells, transfers or distributes goods, 15 including over-the-counter drug products, to an ultimate consumer.
- 16 <u>(r) (s) "Schedule V" "Schedule IV"</u> means the schedule of 17 controlled substances set out in section two hundred twelve ten, 18 section article two of this chapter.
- 19 (s) (t) "Superintendent of the State Police" or 20 "superintendent" means the Superintendent of the West Virginia State 21 Police as set forth in section five, article two, chapter fifteen 22 of this code.
- 23 (t) (u) "Wholesaler" means any person within this state or 24 another state, other than a manufacturer, who sells, transfers or

1 in any manner furnishes a drug product to any other person in this 2 state for the purpose of being resold.

- 3 **§60A-10-4**. Purchase, receipt, acquisition and possession of 4 substances which may be used as a precursor to 5 manufacture of methamphetamine or 6 controlled substance; offenses; exceptions; 7 penalties.
- 8 (a) A pharmacy may not sell, transfer or dispense to the same 9 person, and a person may not purchase more than three and six-tenths 10 grams per day, more than seven and two-tenths grams in a thirty-day 11 period or more than forty-eight grams annually of ephedrine, 12 pseudoephedrine or phenylpropanolamine without a prescription, The 13 limits shall apply to the total amount of ephedrine, pseudoephedrine 14 and phenylpropanolamine contained in the products, and not the 15 overall weight of the products. unless the product has been 16 determined by the Board of Pharmacy to be in an extraction- or 17 conversion-resistant form.
- (1) Any person who or knowingly purchases, receives or 19 otherwise possesses, more than seven and two-tenths grams in a 20 thirty-day period delivers or possesses with the intent to deliver 21 of ephedrine, pseudoephedrine or phenylpropanolamine in any form 22 without a prescription that has not been determined by the Board of 23 Pharmacy to be in an extraction- or conversion-resistant form 24 without a prescription is guilty of a misdemeanor and, upon

1 conviction, shall be confined in a jail for not more than one year,
2 fined not more than \$1,000, or both fined and confined: <u>Provided</u>,
3 <u>That the provisions of subdivision (3)</u>, <u>subsection (a)</u>, <u>section</u>
4 <u>seven</u>, <u>article seven</u>, <u>chapter sixty-one of this code are</u>
5 <u>inapplicable to persons possessing ephedrine</u>, <u>pseudoephedrine or</u>
6 <u>phenylpropanolamine which has been lawfully purchased in the</u>
7 <u>jurisdiction of sale and which is possessed with the intent that it</u>
8 be used in the manner and form intended by the manufacturer.

- 9 (2) Any pharmacy, wholesaler or other entity operating the 10 retail establishment which sells, transfers or dispenses a product 11 in violation of this section is guilty of a misdemeanor and, upon 12 conviction, shall be fined not more than \$1,000 for the first 13 offense, or more than \$10,000 for each subsequent offense.
- 14 (b) Notwithstanding the provisions of subdivision (a)(1)
 15 subdivision (1), subsection (a) of this section, any person
 16 convicted of a second or subsequent violation of the provisions of
 17 said subdivision or a statute or ordinance of the United States or
 18 another state which contains the same essential elements is guilty
 19 of a felony and, upon conviction, shall be imprisoned in a state
 20 correctional facility for not less than one nor more than five
 21 years, fined not more than \$25,000, or both imprisoned and fined.
- 22 (c) The provisions of subsection (a) of this section shall not 23 apply to:
- 24 (1) Products dispensed pursuant to a valid prescription;

(2) Drug products which are for pediatric use primarily 1 2 intended for administration to children under the age of twelve; or (3) Drug products containing ephedrine, pseudoephedrine or 4 phenylpropanolamine, their salts or optical isomers or salts of 5 optical isomers or other designated precursor which have been 6 determined by the Board of Pharmacy to be in a form which is not 7 feasible for being used for the manufacture of methamphetamine; or (4) (3) Persons lawfully possessing drug products in their 9 capacities as distributors, wholesalers, manufacturers, pharmacists, 10 pharmacy interns, pharmacy technicians or health care professionals. (d) Notwithstanding any provision of this code to the contrary, 11 12 any person who knowingly possesses any amount of ephedrine, 13 pseudoephedrine, phenylpropanolamine or other designated precursor 14 with the intent to use it in the manufacture of methamphetamine, or 15 who knowingly compensates, hires or provides other incentives for 16 another person to purchase, obtain or transfer any amount of 17 ephedrine, pseudoephedrine, phenylpropanolamine or other designated 18 precursor with the intent to use it in the manufacture of 19 methamphetamine or who knowingly possesses a substance containing 20 ephedrine, pseudoephedrine or phenylpropanolamine or their salts, 21 optical isomers or salts of optical isomers in a state or form which 22 is or has been altered or converted from the state or form in which 23 these chemicals are, or were, commercially distributed is guilty of 24 a felony and, upon conviction, shall be imprisoned in a state

1 correctional facility for not less than two nor more than ten years, 2 fined not more than \$25,000, or both imprisoned and fined.

- (e) (1) Any pharmacy, wholesaler, manufacturer or distributor 4 of drug products containing ephedrine, pseudoephedrine, 5 phenylpropanolamine, their salts or optical isomers or salts of 6 optical isomers or other designated precursor shall obtain a 7 registration annually from the State Board of Pharmacy as described 8 in section six of this article. Any such pharmacy, wholesaler, 9 manufacturer or distributor shall keep complete records of all sales 10 and transactions as provided in section eight of this article. The 11 records shall be gathered and maintained pursuant to legislative 12 rule promulgated by the Board of Pharmacy.
- 13 (2) Any drug products possessed without a registration as 14 provided in this section are subject to forfeiture upon conviction 15 for a violation of this section.
- 16 (3) In addition to any administrative penalties provided by 17 law, any violation of this subsection is a misdemeanor, punishable 18 upon conviction by a fine in an amount not more than \$10,000.
- 19 §60A-10-5. Restrictions on the commercial sale, transfer or delivery of certain drug products; penalties.
- 21 (a) No pharmacy or individual may display, offer for sale or 22 place a drug product containing ephedrine, pseudoephedrine or 23 phenylpropanolamine or other designated <u>methamphetamine</u> precursor 24 where the public may freely access the drug product. All such drug

1 products or designated precursors shall be placed behind a pharmacy 2 counter where access is restricted to a pharmacist, a pharmacy 3 intern, a pharmacy technician or other pharmacy employee.

- (b) All storage of drug products regulated by the provisions

 5 of this section shall be in a controlled and locked access location

 6 that is not accessible by the general public and shall maintain

 7 strict inventory control standards and complete records of quantity

 8 of the product maintained in bulk form: Provided, That wholesale

 9 drug distributors required to be licensed by the Board of Pharmacy

 10 which are registered with and regulated by the United States Drug

 11 Enforcement Administration shall not be subject to any board

 12 requirements relating to the storage, recordkeeping or physical

 13 security of controlled substances containing ephedrine,

 14 pseudoephedrine or phenylpropanolamine which are more stringent than

 15 those imposed by the U. S. Drug Enforcement Administration.
- 16 (c) No pharmacy may sell, deliver or provide any drug product 17 regulated by the provisions of this section to any person who is 18 under the age of eighteen.
- 19 (d) If a drug product regulated by the provisions of this 20 section is transferred, sold or delivered, the individual, pharmacy 21 or retail establishment transferring, selling or delivering the drug 22 product shall offer to have a pharmacist provide patient counseling, 23 as defined by article five, chapter thirty of this code and the 24 rules of the Board of Pharmacy, to the person purchasing, receiving

1 or acquiring the drug product in order to improve the proper use of 2 the drug product and to discuss contraindications.

- (e) If a drug product regulated by the provisions of this 4 section which the Board of Pharmacy has determined is in an 5 extraction- or conversion-resistant form is transferred, sold or 6 delivered, the individual or pharmacy or retail establishment 7 transferring, selling or delivering the drug product shall require 8 the person purchasing, receiving or otherwise acquiring the drug 9 product to (1) Produce produce a valid government-issued photo 10 identification showing his or her date of birth; and
- 11 (2) Sign a logbook, in either paper or electronic format,
 12 containing the information set forth in subsection (b), section
 13 eight of this article and attesting to the validity of the
 14 information.
- 15 (f) Any person who knowingly makes a false representation or 16 statement pursuant to the requirements of this section is guilty of 17 a misdemeanor and, upon conviction, be confined in a jail for not 18 more than six months, fined not more than \$5,000, or both fined and 19 confined.
- 20 (g) (1) The pharmacist, pharmacy intern or pharmacy technician 21 processing the transaction shall determine that the name entered in 22 the logbook corresponds to the name provided on the identification.
- 23 (2) Beginning January 1, 2013, a pharmacy or retail 24 establishment shall, before completing a sale under this section,

1 electronically submit the information required by section eight of 2 this article to the Multi-State Real-Time Tracking System (MSRTTS) 3 administered by the National Association of Drug Diversion 4 Investigators (NADDI): Provided, That the system is available to 5 retailers in the state without a charge for accessing the system. 6 This system shall be capable of generating a stop-sale alert, which 7 shall be a notification that completion of the sale would result in 8 the seller or purchaser violating the quantity limits set forth in 9 this article. The seller may not complete the sale if the system 10 generates a stop-sale alert. The system shall contain an override 11 function that may be used by a dispenser of a drug product who has 12a reasonable fear of imminent bodily harm if he or she does not 13 complete a sale. Each instance in which the override function is 14 utilized shall be logged by the system. Absent negligence, 15 wantonness, recklessness or deliberate misconduct, any retailer 16 utilizing the Multi-State Real-Time Tracking System in accordance 17 with this subdivision may not be civilly liable as a result of any 18 act or omission in carrying out the duties required by this 19 subdivision and is immune from liability to any third party unless 20 the retailer has violated any provision of this subdivision in 21 relation to a claim brought for the violation.

22 (3) If a pharmacy or retail establishment selling a 23 nonprescription product containing ephedrine, pseudoephedrine or 24 phenylpropanolamine experiences mechanical or electronic failure of

1 the Multi-State Real-Time Tracking System and is unable to comply 2 with the electronic sales tracking requirement, the pharmacy or 3 retail establishment shall maintain a written log or an alternative 4 electronic record-keeping mechanism until such time as the pharmacy 5 or retail establishment is able to comply with the electronic sales 6 tracking requirement.

- 7 (h) This section does not apply to drug products that are 8 dispensed pursuant to a prescription, are or pediatric products 9 primarily intended for administration, according to label 10 instructions, to children under twelve years of age.
- 11 (i) Any violation of this section for which there is not a 12 particularized penalty is a misdemeanor, punishable upon conviction 13 by a fine in an amount not more than \$10,000.
- 14 (j) The provisions of this section supersede and preempt all 15 local laws, ordinances, rules and regulations pertaining to the sale 16 of any compounds, mixtures or preparation containing ephedrine, 17 pseudoephedrine or phenylpropanolamine.

18 §60A-10-7. Restricted products; rule-making authority; effective date of amendments.

(a) On or before July 1, 2005 2014, the Board of Pharmacy shall 21 promulgate emergency and legislative rules pursuant to the provision 22 of article three, chapter twenty-nine-a of this code to a implement 23 continue the program wherein the Board of Pharmacy shall consult 24 consults with the Superintendent of the State Police in identifying

1 drug products which are a designated precursor, in addition to those 2 that contain ephedrine, pseudoephedrine or phenylpropanolamine, that 3 are commonly being used in the production and distribution of 4 methamphetamine. Those drug products which the Superintendent of 5 the State Police have has demonstrated by empirical evidence are 6 commonly used in the manufacture of methamphetamine shall be added 7 to a supplemental list and shall be subject to all of the 8 restrictions of this article. These rules established pursuant to 9 this section shall include:

- (1) A process whereby pharmacies are made aware of all drug 11 products that contain ephedrine, pseudoephedrine and 12 phenylpropanolamine that will be listed as a Schedule ¥ IV 13 substance. and must be sold, transferred or dispensed from behind 14 a pharmacy counter. This process shall specifically state which 15 products have been determined by the Board of Pharmacy to be in a 16 form which is extraction or conversion resistant and may, therefore, 17 be sold without a prescription. The process shall specify that all 18 other drug products which have not been determined by the Board of 19 Pharmacy to be extraction or conversion resistant shall be 20 distributed by prescription only;
- (2) A process whereby pharmacies and retail establishments are 22 made aware of additional drug products added to Schedule ₹ IV, that 23 are required to be placed behind the pharmacy counter for sale, 24 transfer or distribution. can be periodically reviewed and updated.

- 1 (b) At any time after July 1, 2005, the Board of Pharmacy, upon 2 the recommendation of the Superintendent of the State Police, shall 3 promulgate emergency and legislative rules pursuant to the provision 4 of article three, chapter twenty-nine-a of this code to implement 5 an updated supplemental list of products containing the controlled 6 substances ephedrine, pseudoephedrine or phenylpropanolamine as an 7 active ingredient or any other drug used as a precursor in the 8 manufacture of methamphetamine, which the Superintendent of the 9 State Police has demonstrated by empirical evidence is being used 10 in the manufacture of methamphetamine. This list shall also note 11 any products containing ephedrine, pseudoephedrine 12 phenylpropanolamine but which has been determined by the Board of 13 Pharmacy to be in a form which is extraction or conversion 14 resistant. This listing process shall comport with the requirements 15 of subsection (a) of this section.
- 16 (c) The repeal of section eight, article 10, chapter sixty—a
 17 of this code, and the amendments to sections two hundred ten and two
 18 hundred twelve, article two, chapter sixty—a and sections two,
 19 three, four, five and seven, article ten, chapter sixty—a of this
 20 code during the 2014 Regular Session of the Legislature shall be
 21 effective September 1, 2014.